This article is more than 5 years old. Information may no longer be current.

Topical administration of new oligonucleotide effectively treats corneal neovascularization in small study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — Topical administration of a new oligonucleotide, the Gene Signal GS-101, is showing positive results in reducing corneal neovascularization without the hypoxic effects of anti-VEGF agents, according to a study carried out at the University Hospital of Valencia, Spain.

GS-101 acts on RNA regulating the production of VEGF, but unlike classical anti-VEGF agents, it does not completely suppress the VEGF.

"The reduction of VEGF is about 50%. This maintains the quantity of VEGF that is necessary to sustain limbal vasculature," Salvador Garcia-Delpech, MD, said in an interview at the meeting of the French Society of Ophthalmology.

The GS-101 agent is currently used in Valencia to treat corneal neovascularization of different origins. The study presented at the SFO showed the results of seven patients with corneal neovascularization after penetrating keratoplasty.

"The administration of two drops a day for 3 months was effective in treating neovascularization. We had no recurrence and no complications," Dr. Garcia-Delpech said.

The study won the award for the Best Presentation in the European Symposium of the SFO.